Apidra Solostar 5 pen

Apidra Solostar

Description:

Apidra Solostar 100 i.u./ml is a rapid-acting insulin analogue (insulin glulisine) supplied in prefilled disposable pens for subcutaneous injection. It is a prescription antidiabetic medicine used in the management of diabetes mellitus in adults, adolescents, and children from 6 years of age. Apidra Solostar is designed to control post‑meal (prandial) blood glucose levels and is typically used in combination with intermediate- or long-acting basal insulin as part of an intensive insulin therapy regimen. Each Solostar pen delivers multiple doses with accurate dosing increments, supporting convenient and precise diabetes care.

Indications:

• Treatment of diabetes mellitus in adults, adolescents, and children 6 years and older who require insulin for blood glucose control.
• Rapid control of postprandial (after-meal) hyperglycemia in type 1 diabetes.
• Adjunctive therapy in type 2 diabetes when oral antidiabetic medicines alone are insufficient to achieve adequate glycemic control.
• Use as part of a basal–bolus insulin regimen or in combination with oral antidiabetic agents as directed by a physician.

Active Ingredients / Key Components:

• Insulin glulisine (rDNA origin) – 100 i.u./ml (rapid-acting insulin analogue).
• Excipients (exact list and concentrations , please check the product leaflet or the manufacturer’s official website; refer to the official package leaflet for full excipient details).

Dosage & Administration / How to Use:

• Apidra Solostar is for subcutaneous injection only. Do not use intravenously or in insulin infusion pumps unless specifically instructed by a healthcare professional.
• Typical timing: inject within 15 minutes before a meal or up to 20 minutes after starting the meal, as directed by your doctor.
• Dosage is individualized based on blood glucose monitoring, type of diabetes, body weight, diet, physical activity, and concurrent medications. Your physician will determine your total daily dose and prandial (meal-time) doses.
• Rotate injection sites within the same region (abdomen, thigh, or upper arm) to reduce the risk of lipodystrophy and skin thickening.
• Check the insulin in the pen before use: solution should be clear, colorless, and free from particles. Do not use if cloudy, colored, or contains particles.
• Using the Solostar pen:
  • Attach a new sterile needle before each injection.
  • Prime the pen according to the manufacturer’s instructions to ensure proper insulin flow.
  • Dial the prescribed dose using the dose selector.
  • Inject subcutaneously as trained by your healthcare provider and hold the needle in the skin for at least 10 seconds to ensure full dose delivery.
  • Remove and safely discard the needle after each injection. Do not share pens or needles with anyone.
• Use in combination with basal insulin and/or oral antidiabetic medicines only as prescribed.
• Do not change your insulin type, dose, or injection schedule without consulting your doctor.

Clinical Benefits:

• Provides rapid onset of action to control post-meal spikes in blood glucose, helping maintain tighter glycemic control.
• Short duration of action reduces the risk of late postprandial hypoglycemia compared with some regular human insulins.
• Flexible dosing time (shortly before or shortly after meals) offers convenience and better adaptation to daily lifestyle and meal patterns.
• Pre-filled Solostar pen enables accurate dosing, ease of use, and improved adherence to insulin therapy, supporting long-term diabetes management and reducing the risk of diabetes-related complications.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to insulin glulisine or any of the excipients.
• Do not use during episodes of hypoglycemia (low blood sugar). Blood glucose must be corrected before administration.
• Use with caution in patients with renal or hepatic impairment; insulin requirements may be reduced and careful monitoring is required.
• Concomitant use of other medicines (e.g., oral antidiabetics, beta-blockers, ACE inhibitors, corticosteroids, diuretics) may alter insulin requirements and mask hypoglycemia symptoms; consult your doctor for dose adjustments.
• Alcohol intake may enhance or weaken the blood glucose-lowering effect of insulin; use with caution.
• Pregnancy and breastfeeding: consult your doctor before use. Insulin requirements may change during pregnancy and postpartum; close medical supervision is necessary.
• Driving and operating machinery: hypoglycemia may impair concentration and reaction time. Take precautions and discuss with your doctor if you experience frequent hypoglycemia.
• Never share your Apidra Solostar pen or needles with others to avoid cross-contamination and infection.
• Always have a source of fast-acting carbohydrate (e.g., glucose tablets, juice) available in case of hypoglycemia.
• Consult your doctor before use if you have any serious medical conditions, including heart disease, kidney disease, liver disease, or if you are taking multiple medications.
• Keep out of reach of children.

Side Effects:

• Common side effects: hypoglycemia (low blood sugar) with symptoms such as sweating, tremor, hunger, headache, dizziness, palpitations, blurred vision, or confusion. Severe hypoglycemia can lead to loss of consciousness or seizures and requires immediate medical attention.
• Injection site reactions: redness, pain, itching, swelling, or irritation at the injection site. These are usually mild and transient.
• Lipodystrophy or skin thickening at injection sites if the same area is used repeatedly; rotate injection sites to reduce risk.
• Allergic reactions: rash, itching, or swelling. Severe generalized allergic reactions (anaphylaxis) are rare but require urgent medical care.
• Edema (fluid retention) and weight changes may occur with insulin therapy.
• If you experience severe, persistent, or unusual side effects, contact your doctor or seek medical attention immediately.

Storage Instructions:

Store unopened Apidra Solostar pens in a refrigerator at 2–8°c. Do not freeze and do not place near the freezer compartment. Protect from direct heat and light. Once in use, a pen may generally be kept at room temperature (storage conditions and duration as per the official leaflet; follow the manufacturer’s instructions) and must not be refrigerated again. Keep the cap on the pen when not in use. Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: rapid-acting insulin analogue for subcutaneous injection.
• Strength: 100 i.u./ml insulin glulisine.
• Form: prefilled disposable insulin pen (Solostar).
• Pack size: 5 prefilled pens (exact volume per pen is not specified in the provided information; refer to pack for details).
• Intended users: adults, adolescents, and children 6 years and older with diabetes mellitus, under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.